Tessier-Lavigne Marc
SEC CIK 1437435 · EDGAR
BoughtSold
Most active insiders at DNLI, 12 months
| # | Insider | Title | Bought | Sold |
|---|---|---|---|---|
| 1 | Watts Ryan J. | Pres, CEO, Dir | — | $580.8K |
| 2 | Schuth Alexander O. | COFO, Sec | — | $420.6K |
| 3 | Thornberry Nancy | Dir | — | $261.9K |
| 4 | Chin Peter Scott | Chief Medical Off | — | $36.9K |
| 5 | Van Hauwermeiren Timothy | Dir | — | — |
| 6 | Cook Jennifer E. | Dir | — | — |
| 7 | Krognes Steve E. | Dir | — | — |
| 8 | Schenkein David P | Dir | — | — |
| 9 | Klein Peter S | Dir | — | — |
| 10 | BAKER BROS. ADVISORS LP | Dir | — | — |
Tessier-Lavigne Marc made no open-market trades at DNLI in the last 12 months.
Transactions 28
| X | Filed | Traded | Ticker | Company | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2025-06-05 | 2025-06-03 | DNLI | Denali Therapeutics Inc. | Tessier-Lavigne Marc | Dir | A - Grant | $0.00 | +6,037 | 1.89M | +0.3% | $0 |
| D | 2024-06-04 | 2024-05-31 | DNLI | Denali Therapeutics Inc. | Tessier-Lavigne Marc | Dir | A - Grant | $0.00 | +5,967 | 1.88M | +0.3% | $0 |
| D | 2023-06-05 | 2023-06-01 | DNLI | Denali Therapeutics Inc. | Tessier-Lavigne Marc | Dir | A - Grant | $0.00 | +4,216 | 1.87M | +0.2% | $0 |
| D | 2023-01-05 | 2023-01-03 | REGN | Regeneron Pharmaceuticals | Tessier-Lavigne Marc | Dir | A - Grant | $0.00 | +165 | 2,434 | +7% | $0 |
| D | 2023-01-05 | 2023-01-03 | REGN | Regeneron Pharmaceuticals | Tessier-Lavigne Marc | Dir | A - Grant | $0.00 | +165 | 2,434 | +7% | $0 |
| 2022-11-28 | 2022-11-23 | DNLI | Denali Therapeutics Inc. | Tessier-Lavigne Marc | Dir | S - Sale | $30.48 | -20.0K | 1.87M | -1% | -$609.6K | |
| M | 2022-11-03 | 2022-11-01+ | DNLI | Denali Therapeutics Inc. | Tessier-Lavigne Marc | Dir | S - Sale | $30.27 | -20.0K | 1.90M | -1% | -$605.5K |
| DM | 2022-10-03 | 2022-09-29+ | REGN | Regeneron Pharmaceuticals | Tessier-Lavigne Marc | Dir | S - Sale+OE | $702.24 | -10.8K | 4,084 | -73% | -$7.61M |
| DM | 2022-10-03 | 2022-09-29+ | REGN | Regeneron Pharmaceuticals | Tessier-Lavigne Marc | Dir | M - OptEx | $413.33 | +10.8K | 6,067 | New | +$4.48M |
| M | 2022-09-30 | 2022-09-28 | DNLI | Denali Therapeutics Inc. | Tessier-Lavigne Marc | Dir | S - Sale | $30.82 | -20.0K | 1.91M | -1% | -$616.3K |
| M | 2022-08-25 | 2022-08-23 | DNLI | Denali Therapeutics Inc. | Tessier-Lavigne Marc | Dir | S - Sale | $31.61 | -20.0K | 1.93M | -1% | -$632.3K |
| M | 2022-07-27 | 2022-07-25 | DNLI | Denali Therapeutics Inc. | Tessier-Lavigne Marc | Dir | S - Sale | $35.61 | -20.0K | 1.95M | -1% | -$712.1K |
| MA | 2022-06-28 | 2022-03-23 | DNLI | Denali Therapeutics Inc. | Tessier-Lavigne Marc | Dir | S - Sale | $33.83 | -20.0K | 2.04M | -1.0% | -$676.6K |
| M | 2022-06-27 | 2022-06-23+ | DNLI | Denali Therapeutics Inc. | Tessier-Lavigne Marc | Dir | D - Sale to Iss | $30.72 | -60.0K | 1.98M | -3% | -$1.84M |
| D | 2022-06-06 | 2022-06-02 | DNLI | Denali Therapeutics Inc. | Tessier-Lavigne Marc | Dir | A - Grant | $0.00 | +5,986 | 2.03M | +0.3% | $0 |
| M | 2022-03-25 | 2022-03-23 | DNLI | Denali Therapeutics Inc. | Tessier-Lavigne Marc | Dir | S - Sale | $33.83 | -20.0K | 2.02M | -1.0% | -$676.6K |
| D | 2022-03-23 | 2022-03-21 | REGN | Regeneron Pharmaceuticals | Tessier-Lavigne Marc | Dir | M - OptEx | $380.95 | +7,439 | 9,708 | +328% | +$2.83M |
| D | 2022-03-23 | 2022-03-21 | REGN | Regeneron Pharmaceuticals | Tessier-Lavigne Marc | Dir | S - Sale+OE | $690.00 | -7,439 | 2,269 | -77% | -$5.13M |
| DM | 2022-03-18 | 2022-03-16+ | REGN | Regeneron Pharmaceuticals | Tessier-Lavigne Marc | Dir | M - OptEx | $375.77 | +12.2K | 10.1K | New | +$4.58M |
| DM | 2022-03-18 | 2022-03-16+ | REGN | Regeneron Pharmaceuticals | Tessier-Lavigne Marc | Dir | S - Sale+OE | $678.21 | -12.2K | 2,269 | -84% | -$8.27M |
| D | 2022-01-05 | 2022-01-03 | REGN | Regeneron Pharmaceuticals | Tessier-Lavigne Marc | Dir | A - Grant | $0.00 | +191 | 2,269 | +9% | $0 |
| MI | 2021-12-30 | 2021-12-28+ | DNLI | Denali Therapeutics Inc. | Tessier-Lavigne Marc | Dir | S - Sale | $44.43 | -63.1K | 96.4K | -40% | -$2.81M |
| MI | 2021-12-30 | 2021-10-04 | DNLI | Denali Therapeutics Inc. | Tessier-Lavigne Marc | Dir | G - Gift | $0.00 | +300.0K | 100.0K | New | $0 |
| 2021-12-30 | 2021-10-04 | DNLI | Denali Therapeutics Inc. | Tessier-Lavigne Marc | Dir | G - Gift | $0.00 | -300.0K | 2.24M | -12% | $0 | |
| D | 2021-12-10 | 2021-12-09 | REGN | Regeneron Pharmaceuticals | Tessier-Lavigne Marc | Dir | S - Sale+OE | $665.00 | -3,784 | 2,078 | -65% | -$2.52M |
| D | 2021-12-10 | 2021-12-09 | REGN | Regeneron Pharmaceuticals | Tessier-Lavigne Marc | Dir | M - OptEx | $371.40 | +3,784 | 5,862 | +182% | +$1.41M |
| DM | 2021-09-15 | 2021-09-13 | REGN | Regeneron Pharmaceuticals | Tessier-Lavigne Marc | Dir | S - Sale+OE | $641.71 | -12.8K | 6,260 | -67% | -$8.18M |
| DM | 2021-09-15 | 2021-09-13 | REGN | Regeneron Pharmaceuticals | Tessier-Lavigne Marc | Dir | M - OptEx | $273.67 | +12.8K | 14.8K | +614% | +$3.49M |
Purchase Sale Sale after option exercise All abbreviations